+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

Neuroendocrine Tumor Treatment Market in Japan - Product Thumbnail Image

Neuroendocrine Tumor Treatment Market in Japan

  • Report
  • February 2026
  • 150 Pages
  • Japan
From
Neoantigen Targeted Therapy Market in Germany - Product Thumbnail Image

Neoantigen Targeted Therapy Market in Germany

  • Report
  • December 2025
  • 150 Pages
  • Germany
From
Neoantigen Targeted Therapy Market in India - Product Thumbnail Image

Neoantigen Targeted Therapy Market in India

  • Report
  • November 2025
  • 150 Pages
  • India
From
Neoantigen Targeted Therapy Market in China - Product Thumbnail Image

Neoantigen Targeted Therapy Market in China

  • Report
  • November 2025
  • 150 Pages
  • China
From
From
From
From
From
From
From
From
USA Solid Tumor Therapeutics Market Outlook to 2028 - Product Thumbnail Image

USA Solid Tumor Therapeutics Market Outlook to 2028

  • Report
  • October 2023
  • 85 Pages
  • United States
From
Disease Analysis: Non-Small Cell Lung Cancer (NSCLC) - Product Thumbnail Image

Disease Analysis: Non-Small Cell Lung Cancer (NSCLC)

  • Report
  • April 2021
  • 191 Pages
  • Global
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more